奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

吴思凡; 谭长宇; 樊红彬; 印晓星; 鲁茜

doi:10.3969/j.issn.1006-0111.2018.04.020

奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

doi: 10.3969/j.issn.1006-0111.2018.04.020

1.
徐州医科大学江苏省新药研究与临床药学重点实验室, 江苏徐州 221004
2.
徐州医科大学附属医院神经内科, 江苏徐州 221006

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

1.
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
2.
Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China

摘要: 目的系统评价奥卡西平与卡马西平治疗脑卒中后继发性癫痫的疗效和安全性。方法计算机检索PubMed、Cochrane Library、EMbase、万方、中国知网、维普、中国生物医学文献数据库（CBM）等收录的奥卡西平和卡马西平治疗脑卒中后继发性癫痫的相关文献，检索时限为建库以来到2017年8月，使用RevMan5.3软件进行Meta分析。结果共纳入6项研究，包含517例患者。Meta分析结果显示：奥卡西平组控制癫痫的总体有效率高于卡马西平组，差异有统计学意义（RR=1.44，95%CI：1.29~1.60，P<0.000 01）；奥卡西平组总不良反应发生率低于卡马西平组，差异有统计学意义（RR=0.39，95%CI：0.26~0.57，P<0.000 01）；皮疹、头晕、嗜睡、恶心、呕吐发生率的比较差异均无统计学意义。结论奥卡西平治疗脑卒中后继发性癫痫的疗效优于卡马西平，安全性较卡马西平好。由于本研究纳入的文献数量和样本量较少，因此还需更多大样本、多中心的高质量临床随机对照试验（randomized controlled trials，RCT）进一步研究验证。
- 奥卡西平 /
- 卡马西平 /
- 脑卒中后继发性癫痫 /
- 疗效 /
- 安全性 /
- Meta分析
Abstract: Objective To evaluate the efficacy and safety of oxcarbazepine and carbamazepine in treating post-stroke epilepsy. Methods PubMed, Cochrane Library, EMbase, VIP, CNKI and CBM were used for searching literatures related to oxcarbazepine and carbamazepine in the treatment of post-stroke epilepsy before August 2017, followed with RevMan5.3 software for data analysis. Results 6 studies were included with 517 patients. Meta-analysis showed that the total effective rate in oxcarbazepine group was higher than carbamazepine group with statistical significance (RR=1.44,95%CI:1.29~1.60,P<0.000 01). The incidence of total adverse reactions in oxcarbazepine group was also statistically significant lower than carbamazepine group (RR=0.39,95%CI:0.26~0.57,P<0.000 01). There was no statistically significant difference (P>0.05) in rash, dizziness, somnolence, nausea and vomiting between two groups. Conclusion Our analysis indicated that oxcarbazepine had better efficacy than carbamazepine in treating post-stroke epilepsy with less adverse reactions. Due to the limited number of literatures and sample size, large samples with multi-center and high quality clinical randomized controlled trials are needed to confirm the credibility of our conclusions.
- oxcarbazepine /
- carbamazepine /
- post-stroke epilepsy /
- efficacy /
- safety /
- Meta-analysis

[1]	ZELANO J. Poststroke epilepsy:update and future directions[J]. Ther Adv Neurol Disord,2016,9(5):424-435.
[2]	ZELANO J,LUNDBERG RG,BAARS L,et al. Clinical course of poststroke epilepsy:a retrospective nested case-control study[J]. Brain Behav,2015,5(9):e00366.
[3]	中华医学会神经病学分会脑电图与癫痫学组. 抗癫痫药物应用专家共识[J].中华神经科杂志,2011,44(1):20-21.
[4]	杨丹. 奥卡西平和卡马西平治疗脑卒中后继发性癫痫的疗效对比和康复分析[J]. 中国伤残医学,2017,25(1):49-50.
[5]	侯蕴祈. 奥卡西平与卡马西平单药治疗脑梗死后迟发型癫痫的对照研究[J]. 中国当代医药,2010,17(15):52-53.
[6]	丁年东. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫的疗效对比观察[J]. 临床合理用药杂志,2016,9(24):42-43.
[7]	马刚. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫对比研究[J]. 中国实用神经疾病杂志,2015,18(14):24-25.
[8]	王艳,赵新利,吴新艳,等. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫疗效比较[J].新乡医学院学报,2014,31(4):312-314.
[9]	韦韬,邱小鹰,陈红,等. 奥卡西平与卡马西平在脑卒中后继发性癫痫的疗效观察[J]. 医学信息,2016,29(9):267-267.
[10]	SZOEKE CE,NEWTON M,WOOD JM,et al. Update on pharmacogenetics in epilepsy:a brief review[J]. Lancet Neurol,2006,5(2):189-196.
[11]	BOOTSMA HP,RICKER L,DIEPMAN L,et al. Levetiracetam in clinical practice:long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center[J]. Epilepsy Behav,2007,10(2):296-303.
[12]	ROUAN MC,LECAILLON JB,GODBILLON J,et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites[J]. Eur J Clin Pharmacol,1994,47(2):161-167.
[13]	ANTUNES NJ,VAN DIJKMAN SC,LANCHOTE VL,et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects[J]. Eur J Pharm Sci,2017,109S:S116-S123.
[14]	RYVLIN P,MONTAVONT A,NIGHOGHOSSIAN N. Optimizing therapy of seizures in stroke patients[J]. Neurology,2006,67(4):3-9.

[1]	孟园园, 吴芸杨, 陈婷如, 顾秦五风, 杨延龙. 九味永安颗粒联合西替利嗪治疗湿疹湿热蕴肤证的临床疗效观察 . 药学实践与服务, 2025, 43(6): 298-302. doi: 10.12206/j.issn.2097-2024.202407045
[2]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[3]	冯广伟, 张静, 刘阳熙, 崔敏. 消化道穿孔患者术后继发念珠菌血流感染的病例分析 . 药学实践与服务, 2025, 43(9): 463-465. doi: 10.12206/j.issn.2097-2024.202312012
[4]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(8): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[5]	李娜, 黄诚文, 孙秀娟, 王晓红, 张丽, 王兴坡. 奥希替尼与吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的成本效果分析 . 药学实践与服务, 2025, 43(12): 608-613. doi: 10.12206/j.issn.2097-2024.202411032
[6]	郭静, 康金龙, 李强, 赵琳, 刘骥, 徐学武. 利多卡因不同给药途径对麻醉诱导气管插管心血管应激反应的抑制作用 . 药学实践与服务, 2025, 43(6): 303-306. doi: 10.12206/j.issn.2097-2024.202502009
[7]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2025, 43(3): 136-142, 150. doi: 10.12206/j.issn.2097-2024.202310043
[8]	刘桂株, 李行, 王楠, 王芳, 胡旭, 汤佳洁. 信息技术在我国用药安全领域应用的计量分析 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202303027
[9]	闻韬, 焦广洋, 赵梦沛, 岳小强, 张凤, 陈万生. 基于UHPLC-Q-TOF/MS结合网络药理学研究柴胡桂枝干姜汤治疗慢性非萎缩性胃炎的物质基础及疗效机制 . 药学实践与服务, 2025, 43(9): 455-462. doi: 10.12206/j.issn.2097-2024.202312061
[10]	葛鹏程, 苏日古嘎, 任天舒, 党大胜. 硫酸黏菌素联合头孢哌酮舒巴坦治疗泛耐药鲍曼不动杆菌肺内感染的疗效分析 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202404093
[11]	于翔, 贾培培, 李欣颖, 杨君君, 郭高峰, 陆连芳. M2型巨噬细胞外泌体喷剂对压力性损伤的疗效及作用机制 . 药学实践与服务, 2025, 43(9): 436-442. doi: 10.12206/j.issn.2097-2024.202503066
[12]	底雪梅, 帅文, 张其锵, 余梅香, 张海, 聂永红. 暖宫外敷方预防宫腔再粘连临床疗效回顾性分析 . 药学实践与服务, 2025, 43(7): 353-356. doi: 10.12206/j.issn.2097-2024.202411013
[13]	陈官旭, 宋雨桐, 郭秀强, 张咪, 刘志宏, 宋洪涛. EGFR-TKIs单药及其联合方案在晚期非小细胞肺癌一线治疗中的疗效与安全性比较：网状Meta分析 . 药学实践与服务, 2025, 43(): 1-11. doi: 10.12206/j.issn.2097-2024.202504044
[14]	周丽城, 欧已铭, 王园. 玉米须黄酮化学成分与药理作用研究进展 . 药学实践与服务, 2025, 43(2): 51-58. doi: 10.12206/j.issn.2097-2024.202309037
[15]	陈婷如, 顾秦五风, 吴芸杨, 孟园园, 杨延龙, 李睿旻. 中药外治法治疗湿疹引起皮肤瘙痒的Meta分析 . 药学实践与服务, 2025, 43(8): 383-389. doi: 10.12206/j.issn.2097-2024.202504013
[16]	王晓丹, 刘文杰, 宋畅, 董文星, 赵倩, 马骁龙. 利多卡因凝胶贴膏联合普瑞巴林治疗带状疱疹后神经痛患者疗效及对血清疼痛介质的影响 . 药学实践与服务, 2025, 43(11): 572-576. doi: 10.12206/j.issn.2097-2024.202505036
[17]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[18]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 . 药学实践与服务, 2024, 42(12): 524-527, 532. doi: 10.12206/j.issn.2097-2024.202405035
[19]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[20]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044

点击查看大图

计量

文章访问数: 4816
HTML全文浏览量: 698
PDF下载量: 530
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

doi: 10.3969/j.issn.1006-0111.2018.04.020

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

计量

奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

doi: 10.3969/j.issn.1006-0111.2018.04.020

1. 徐州医科大学江苏省新药研究与临床药学重点实验室, 江苏徐州 221004

2. 徐州医科大学附属医院神经内科, 江苏徐州 221006

English Abstract

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China

2. Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China

全文HTML

目录

留言板

奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

doi: 10.3969/j.issn.1006-0111.2018.04.020

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

计量

出版历程

奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析

doi: 10.3969/j.issn.1006-0111.2018.04.020

1. 徐州医科大学江苏省新药研究与临床药学重点实验室, 江苏 徐州 221004 2. 徐州医科大学附属医院神经内科, 江苏 徐州 221006

English Abstract

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China 2. Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China

全文HTML

目录

1. 徐州医科大学江苏省新药研究与临床药学重点实验室, 江苏徐州 221004

2. 徐州医科大学附属医院神经内科, 江苏徐州 221006

1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China

2. Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China